User login
The dermMentors™ Resident of Distinction Award™ was presented to 5 dermatology residents at the virtual 16th Annual Coastal Dermatology Symposium, October 15–16, 2020. Recipients of the award include Shaundra Eichstadt, MD, Stanford University Department of Dermatology, Redwood City, California, and Tufts University Medical Center, Boston, Massachusetts; Nicholas Gulati, MD, PhD, NYU Grossman School of Medicine, New York, New York; Anthony K. Guzman, MD, Albert Einstein College of Medicine, Bronx, New York; Nikolai Klebanov, MD, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts; and Reid Waldman, MD, University of Connecticut, Farmington. The residents presented their research during the general sessions on October 16, 2020.
The overall grand prize was awarded to Dr. Guzman for his research entitled, “Topical Cantharidin Revisited: A Phase 2 Study Investigating a Commercially Viable Formulation of Cantharidin (VP-102) for the Treatment of Molluscum Contagiosum.” Dr. Guzman presented the results of a 12-week, open-label pilot trial at a single outpatient dermatology clinic to determine the efficacy and safety of VP-102, a novel, standardized, commercially viable cantharidin formulation produced under good manufacturing practice for the treatment of molluscum contagiosum. “VP-102 was well tolerated with either a 6- or 24-hour exposure and was associated with a significantly reduced lesion count, improved quality of life, and complete clearance of MC lesions in nearly half of the patients,” Dr. Guzman reported.
Presentations by the other residents included results of a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa (Dr. Eichstadt), an analysis of the association between skin toxicity and better response in melanoma patients treated with immune checkpoint inhibitors (Dr. Gulati), a study of the risks of COVID-19 infection and mortality for patients on biologics (Dr. Klebanov), and a comparison of compliance rates of atopic dermatitis patients on systemic medications with those of psoriasis patients on systemic medications (Dr. Waldman). Access all of the abstracts presented by the top residents here.
The dermMentors™ Resident of Distinction Award™ recognizes top residents in dermatology. DermMentors.org and the dermMentors™ Resident of Distinction Award™ are sponsored by Beiersdorf Inc and administered by DermEd, Inc. The 2020 dermMentors™ Residents of Distinction™ presented new scientific research during the general sessions of the virtual 16th Annual Coastal Dermatology Symposium on October 16, 2020.
The dermMentors™ Resident of Distinction Award™ was presented to 5 dermatology residents at the virtual 16th Annual Coastal Dermatology Symposium, October 15–16, 2020. Recipients of the award include Shaundra Eichstadt, MD, Stanford University Department of Dermatology, Redwood City, California, and Tufts University Medical Center, Boston, Massachusetts; Nicholas Gulati, MD, PhD, NYU Grossman School of Medicine, New York, New York; Anthony K. Guzman, MD, Albert Einstein College of Medicine, Bronx, New York; Nikolai Klebanov, MD, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts; and Reid Waldman, MD, University of Connecticut, Farmington. The residents presented their research during the general sessions on October 16, 2020.
The overall grand prize was awarded to Dr. Guzman for his research entitled, “Topical Cantharidin Revisited: A Phase 2 Study Investigating a Commercially Viable Formulation of Cantharidin (VP-102) for the Treatment of Molluscum Contagiosum.” Dr. Guzman presented the results of a 12-week, open-label pilot trial at a single outpatient dermatology clinic to determine the efficacy and safety of VP-102, a novel, standardized, commercially viable cantharidin formulation produced under good manufacturing practice for the treatment of molluscum contagiosum. “VP-102 was well tolerated with either a 6- or 24-hour exposure and was associated with a significantly reduced lesion count, improved quality of life, and complete clearance of MC lesions in nearly half of the patients,” Dr. Guzman reported.
Presentations by the other residents included results of a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa (Dr. Eichstadt), an analysis of the association between skin toxicity and better response in melanoma patients treated with immune checkpoint inhibitors (Dr. Gulati), a study of the risks of COVID-19 infection and mortality for patients on biologics (Dr. Klebanov), and a comparison of compliance rates of atopic dermatitis patients on systemic medications with those of psoriasis patients on systemic medications (Dr. Waldman). Access all of the abstracts presented by the top residents here.
The dermMentors™ Resident of Distinction Award™ recognizes top residents in dermatology. DermMentors.org and the dermMentors™ Resident of Distinction Award™ are sponsored by Beiersdorf Inc and administered by DermEd, Inc. The 2020 dermMentors™ Residents of Distinction™ presented new scientific research during the general sessions of the virtual 16th Annual Coastal Dermatology Symposium on October 16, 2020.
The dermMentors™ Resident of Distinction Award™ was presented to 5 dermatology residents at the virtual 16th Annual Coastal Dermatology Symposium, October 15–16, 2020. Recipients of the award include Shaundra Eichstadt, MD, Stanford University Department of Dermatology, Redwood City, California, and Tufts University Medical Center, Boston, Massachusetts; Nicholas Gulati, MD, PhD, NYU Grossman School of Medicine, New York, New York; Anthony K. Guzman, MD, Albert Einstein College of Medicine, Bronx, New York; Nikolai Klebanov, MD, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts; and Reid Waldman, MD, University of Connecticut, Farmington. The residents presented their research during the general sessions on October 16, 2020.
The overall grand prize was awarded to Dr. Guzman for his research entitled, “Topical Cantharidin Revisited: A Phase 2 Study Investigating a Commercially Viable Formulation of Cantharidin (VP-102) for the Treatment of Molluscum Contagiosum.” Dr. Guzman presented the results of a 12-week, open-label pilot trial at a single outpatient dermatology clinic to determine the efficacy and safety of VP-102, a novel, standardized, commercially viable cantharidin formulation produced under good manufacturing practice for the treatment of molluscum contagiosum. “VP-102 was well tolerated with either a 6- or 24-hour exposure and was associated with a significantly reduced lesion count, improved quality of life, and complete clearance of MC lesions in nearly half of the patients,” Dr. Guzman reported.
Presentations by the other residents included results of a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa (Dr. Eichstadt), an analysis of the association between skin toxicity and better response in melanoma patients treated with immune checkpoint inhibitors (Dr. Gulati), a study of the risks of COVID-19 infection and mortality for patients on biologics (Dr. Klebanov), and a comparison of compliance rates of atopic dermatitis patients on systemic medications with those of psoriasis patients on systemic medications (Dr. Waldman). Access all of the abstracts presented by the top residents here.
The dermMentors™ Resident of Distinction Award™ recognizes top residents in dermatology. DermMentors.org and the dermMentors™ Resident of Distinction Award™ are sponsored by Beiersdorf Inc and administered by DermEd, Inc. The 2020 dermMentors™ Residents of Distinction™ presented new scientific research during the general sessions of the virtual 16th Annual Coastal Dermatology Symposium on October 16, 2020.